Chromadex Corp
NASDAQ:CDXC
Chromadex Corp
NASDAQ:CDXC
Price:
3.78 USD
0.53%
Market Closed
Updated:
May 5, 2024
Chromadex Corp
Income from Continuing Operations
|
Chromadex Corp
Income from Continuing Operations Peer Comparison
Comparables:
TMO
DHR
MTD
A
IQV
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Chromadex Corp
NASDAQ:CDXC
|
Income from Continuing Operations
-$4.9m
|
CAGR 3-Years
37%
|
CAGR 5-Years
32%
|
CAGR 10-Years
-1%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Income from Continuing Operations
$6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
|
Danaher Corp
NYSE:DHR
|
Income from Continuing Operations
$7.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
28%
|
CAGR 10-Years
12%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Income from Continuing Operations
$788.8m
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Income from Continuing Operations
$1.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
1%
|
CAGR 10-Years
22%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Income from Continuing Operations
$1.4B
|
CAGR 3-Years
65%
|
CAGR 5-Years
42%
|
CAGR 10-Years
20%
|
See Also
What is Chromadex Corp's Income from Continuing Operations?
Income from Continuing Operations
-4.9m
USD
-4.9m
USD
Based on the financial report for Dec 31, 2023, Chromadex Corp's Income from Continuing Operations amounts to -4.9m USD.
What is Chromadex Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-1%
-1%
Over the last year, the Income from Continuing Operations growth was 70%. The average annual Income from Continuing Operations growth rates for Chromadex Corp have been 37% over the past three years , 32% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet
